MedTrace Logo

A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight

NCT06547775 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-09-17

No results posted yet for this study

Summary

This is a Phase 1, First-in-human, double-blinded, placebo-controlled study which aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the immunogenicity of KN069 in Chinese male participants with Obesity or Overweight.

Conditions

  • Overweight or Obesity

Interventions

DRUG

KN069

Solution for SC injection

Sponsors & Collaborators

  • Suzhou Alphamab Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • GuoPing Yang, Doctor · Xiangya Third Hospital, Central South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-02
Primary Completion
2027-04-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06547775 on ClinicalTrials.gov